Site Map
Search
Site Outline
Home
Company
Overview
Mission
History
Focus Areas
Patents and Trademarks
Management Team
Board of Directors
Technology
Nanoparticles
Gold Nanoparticle Technology Overview
Direct Detection of Nucleic Acids
Chemistry
Applications
Bibliography
Request Information
Ultra-sensitive Protein Detection
Chemistry
Applications
Bibliography
Products
Verigene
®
System
Overview of the Verigene
®
Reader
Overview of the Verigene
®
Processor
Overview of a Verigene
®
Test Cartridge
Overview of the Verigene
®
System Workflow
Verigene
®
Nucleic Acid Tests
Genetics
Pharmacogenetics
Infectious diseases
Oncology
Investor Relations / Media
Investor Overview
Stock Information
Corporate Governance
Press Releases
Presentations
Annual Reports/Proxy
SEC Filings
Upcoming Events
Contact Us
Contact Request Form
Careers
Facilities Manager
SEC Filings
Form 10-K
NANOSPHERE INC filed this
Form 10-K
on 03/11/10
Document Outline
Entire Document (1003.4 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - N/A
Page 2 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Page 3 - NANOSPHERE, INC. INDEX
Page 4 - Forward-Looking Statements
Page 5 - N/A
Page 6 - N/A
Page 7 - Our Applications
Page 8 - Genomic Assays
Page 9 - Protein Assays
Page 10 - Connective-tissue.
Page 11 -
Page 12 - Schematic of Microarray Based Detection Using Nanoparticle Probes
Page 13 -
Page 14 - Sales and Marketing
Page 15 - 5
Page 16 - Clinical Investigations
Page 17 - Export of Our Products
Page 18 - Item 1A.
Page 19 - We and our customers are subject to various governmental regulations, and we may incur significant e
Page 20 - We may fail to receive positive clinical results from the diagnostic tests currently in development
Page 21 - The adverse capital and credit market conditions could affect our liquidity.
Page 22 - N/A
Page 23 - We have limited experience in sales and marketing and may be unable to successfully commercialize ou
Page 24 - We will need to develop manufacturing capacity by ourselves or with third parties.
Page 25 - We may not be able to manage our anticipated growth, and we may experience constraints or inefficien
Page 26 - Healthcare reform and restrictions on reimbursement may adversely affect our profitability.
Page 27 - If equity research analysts do not publish research or reports about our business or if they issue u
Page 28 - Our 2007 Long-Term Incentive Plan includes an automatic share replenishment, or evergreen, provisi
Page 29 - Concentration of ownership among some of our stockholders, including directors and management may li
Page 30 - PART II
Page 31 - Stock Performance Graph
Page 32 - Item 6.
Page 33 - Item 7.
Page 34 - de novo
Page 35 - Financial Operations Overview
Page 36 - Sales, General and Administrative Expenses
Page 37 - Interest Expense
Page 38 - N/A
Page 39 -
Page 40 - Contractual Obligations and Commitments
Page 41 - Stock-Based Compensation Expense
Page 42 - Item 7A.
Page 43 - Item 8.
Page 44 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 45 - N/A
Page 46 - Nanosphere, Inc.
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - N/A
Page 53 - N/A
Page 54 - N/A
Page 55 - N/A
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - N/A
Page 60 - N/A
Page 61 - N/A
Page 62 - Item 9.
Page 63 - N/A
Page 64 - PART III.
Page 65 - PART IV.
Page 66 - Exhibit Number
Page 67 - N/A
Page 68 - SIGNATURES
Subdocument 2 - EX-23.1 - EXHIBIT 23.1
Page 1 - Exhibit 23.1
Subdocument 3 - EX-31.1 - EXHIBIT 31.1
Page 1 - Exhibit 31.1
Subdocument 4 - EX-31.2 - EXHIBIT 31.2
Page 1 - Exhibit 31.2
Subdocument 5 - EX-32.1 - EXHIBIT 32.1
Page 1 - Exhibit 32.1
Subdocument 6 - EX-32.2 - EXHIBIT 32.2
Page 1 - Exhibit 32.2
Investor Overview
Stock Information
Corporate Governance
Press Releases
Presentations
Annual Reports/Proxy
SEC Filings
Upcoming Events
Print Page
E-mail Page
RSS News Feed
E-mail Alerts